Chief Technical Ops Officer

PRESIDENT AND CFO

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Institution	Shares	Value	Change
BlackRock	12,068,129	$702M	INCREASED
State Street	5,351,698	$311M	INCREASED
Pictet Asset Management Holding	694,719	$40M	DECREASED
BNY Mellon	502,135	$29M	INCREASED
Jennison Associates	476,216	$28M	DECREASED

Insider	Type	Shares	Value	Date
Harpreet S. Dhaliwal (Chief Technical Ops Officer)	EXERCISE	17,000	$421K	2026-08-05
Harpreet S. Dhaliwal (Chief Technical Ops Officer)	SELL	17,000	$935K	2026-08-05
Andrew Guggenhime (PRESIDENT AND CFO)	EXERCISE	10,000	$54K	2026-08-03
Andrew Guggenhime (PRESIDENT AND CFO)	SELL	3,044	$165K	2026-08-03
Andrew Guggenhime (PRESIDENT AND CFO)	SELL	6,956	$374K	2026-08-03

Member	Type	Amount	Date
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-05-13
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-05-12

Vaxcyte, Inc. Common Stock (PCVX) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades